29 May 2019
Visiongain has launched a new pharma report Global Respiratory Drug Delivery Market: Suspension Aerosol, Solution Aerosol, Dry Powder Formulation, Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories, Plain Canister, Coated Canister, Asthma, COPD, Cystic Fibrosis, Other Applications, Hospitals & Clinics, Homecare Settings.
The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.
The lead analyst of the report commented "Technological advances in drug delivery will have a positive impact on the market for pulmonary drug delivery devices. These advances include the electronic dose counter MDI, incorporation of agglomerated vesicle technology, and technology for supercritical fluids. Moreover, increasing demand for advanced drug delivery devices, improving healthcare infrastructure, ease of use, and increase in healthcare spending are some of the major factors that will provide lucrative opportunities in the near future."
Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva and other companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market